Contezolid and contezolid acefosamil

Next generation oral and IV oxazolidinone with improved safety to treat methicillin-resistant S. aureus (MRSA)

Reduced risk of myelosuppression was shown in both preclinical & clinical studies including a Phase3 registration study in complicated skin infections

  • Antimicrobial compound/strategy

  • Bacteria

  • Human

Development stage:
  • Development
  • Marketed product

  • Company

  • License, Co-develop, Joint Venture, Sell

Funding organisation:
  • CARB-X

Infectious disease area:
  • UTI
  • BSI
  • RTI
  • SSTI
  • IAI
  • SSI

Geographic origin:
  • North America

Contezolid (oral), contezolid acefosamil (intravenous) and MRX-8 (intravenous) are available for licensing and/or co-development outside of greater China.

Pharmaceutical development and commericalization company focused on antibiotics and rare diseases

Next generation intravenous polymyxin to treat multidrug-resistant Gram-negative infections with the potential for reduced nephtrotoxicity, while maintaining excellent efficacy.

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!